As the complexity of the active kinome has become more apparent, the PamGene system is the only profiling platform available to measure direct phosphorylation activity in real-time and unbiasedly address hundreds of protein kinases simultaneously within biological samples. Profiling of the active kinome provides a novel vehicle for a deeper understanding of biological systems and a promising new avenue for drug target discovery. In this webinar, Dr. Christin Luft from the High-Content Biology Facility and Jasper Snoep representative from PamGene, will introduce how you can access this novel technology right here at UCL.
7
10/14/2025
The speakers will introduce a new 19F NMR fragment screening platform at the UCL School of Pharmacy, which provides an efficient approach to drug discovery by screening a small but chemically diverse library of ca. 500 compounds for weak but atom-efficient binders.
The talk will cover the principles of fragment-based drug discovery and NMR spectroscopy, practical aspects of the rapid, multiplexed screening workflow – which requires just 2-3 mg of sample – and the downstream analysis and software used to identify hits. The speakers will examine a number of case studies involving screening against both protein and nucleic acid targets, and additional capabilities of NMR to drug discovery and development will also be discussed, highlighting the broader utility of this technique beyond initial fragment screening.
8
10/14/2025
In this session, Prof. Selina Wray (Professor of Molecular Neuroscience and Alzheimer’s Research UK Senior Research Fellow, UCL Queen Square Institute of Neurology) will share insights from their team’s experience modelling Alzheimer’s disease, highlighting key challenges and lessons learned. The talk will also explore important considerations around robustness and reproducibility when working with iPSCs, and will conclude with an overview of their plans for moving to high-throughput cell culture.
This webinar series is organised by the UCL Therapeutic Innovation Networks (TINs) - Small Molecules to highlight UCL’s Research Capabilities that enable effective translational research for patient and public benefit. The series aims to encourage multidisciplinary collaborations within and beyond UCL. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
26
7/16/2025
The development of mRNA based vaccines delivered in lipid nanoparticles (LNPs) has led to a surge of interest in the possible use of LNP mRNA formulation as a treatment for a range of other diseases. During this webinar, Prof. Steve Hart from the Department of Genetics & Genomic Medicine, will introduce nanoparticle technologies and the design and production of mRNA for their use in the development of therapeutics.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
34
8/2/2024
This session will unravel the complexities of developing inhaled formulations of biologics for the treatment of respiratory diseases such as severe asthma, viral infections, and cystic fibrosis. In her presentation, Dr Jenny Lam from the School of Pharmacy will give an overview of the use of particle engineering techniques and formulation strategies to overcome the delivery barriers. She will also introduce the spray drying technology, a versatile and scalable particle engineering technique that has been investigated for producing dry powder formulation of biologics with good stability (avoid cold-chain logistics) and aerosolisation properties for inhalation.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments.
24
5/23/2024
In this presentation, Prof. Thalassinos from the Institute of Structural and Molecular Biology explored the functionalities of the UCL Mass Spectrometry Science Technology Platform, focusing on its mass spectrometry capabilities. He will also highlight several recent research projects that have been made possible due to this remarkable technology.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
9
5/23/2024
UCL is launching a major new initiative called TINs Industry Club, an opportunity for industry partners to engage the UCL Therapeutic Innovation Networks (TINs) to identify & address company R&D challenges, and to hear the latest UCL research for potential co-development.
In this webinar, we showcased six areas of strength for the therapeutic modality Small Molecules that we think are ripe for collaboration.
9
5/23/2024
Antisense oligonucleotides (AONs) can be used to alter many aspects of gene expression, from splice isoform switching to reducing, or increasing, gene expression. The retina is an accessible part of the nervous system and is an ideal paradigm to study how AONs can be used to combat neurodegeneration.
During this webinar, Prof. Mike Cheetham from the Institute of Ophthalmology will give an overview of AON design and show how they can be used as therapies for inherited retinal dystrophies (IRDs), from stem cell derived models of disease, to in vivo and clinical trials. This will exemplify the potential of AONs to treat genetic disease, and IRDs in particular.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biome
26
3/27/2024